NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Inhibrx Biosciences, Inc. (INBX) Stock Analysis

Inhibrx Biosciences, Inc. (INBX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

INBX

$98.19

+$2.89 (+3.03%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare INBX with… →

INBX Key Statistics

As of Oct 21, 2026
Trading
Open
$93.00
Previous Close
$95.30
Day's Range
93.00–99.68
52-Week Range
28.16–155.29
Volume
239.30K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
3.82
Valuation
Market Cap
$1.45B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−8.88
Financials (FY)
Revenue (FY)
$1.30M+550.00%
Net Income (FY)
−$140.06M−108.30%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
14.72M
1-Year Return
+161.70%
Dividend and dates
Earnings Date
November 13, 2026
Avg Volume
274.51K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, INBX closed at $98.19, +161.70% over 1 year.

Inhibrx Biosciences, Inc. (INBX) has a market capitalization of $1.45B.

In fiscal 2025, INBX reported revenue of $1.30M.

INBX Stock Return by Calendar Year

Inhibrx Biosciences, Inc. (INBX) return since May 2024: what $10,000 became

1 year
$10,000 $26,170
+161.70%
Since May 2024
$10,000 $78,510
+685.10%

If you had invested $10,000 in Inhibrx Biosciences, Inc. (INBX) at the close on May 29, 2024, the earliest close on record here, it would have been worth $78,510 at the close on October 21, 2026: +685.10% in total, +136.36% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+24.29%
2025+412.99%
2024 (partial year)+23.13%

As of October 21, 2026.

INBX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.30M−$140.06M−10,773.5%
2024$200.00K$1.69B843,786.0%
2023$1.80M−$241.36M−13,408.9%
2022$1.30M−$115.33M−8,864.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.30M—−$135.03M−$140.06M−10,773.5%
2024$200.00K—−$331.45M$1.69B843,786.0%
2023$1.80M—−$219.22M−$241.36M−13,408.9%
2022$1.30M—−$115.32M−$115.33M−8,864.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 14 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Inhibrx Biosciences, Inc. (INBX) is capitalised at $1.45B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 109.

INBX last closed at $98.19 on October 21, 2026. That is +$2.89 (+3.03%) against the previous close. The 52-week range on file runs from $28.16 to $155.29. The latest close sits 248.69% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $1.30M. Against the prior fiscal year total of $200.00K, that is a change of +550.00%. The same year closed with a net loss of $140.06M. Earnings per share on a trailing basis come to −8.88.

Across the 4 fiscal years on file, revenue moves from $1.30M in 2022 to $1.30M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Over the trailing twelve months the total return is +161.70%. The stored price history starts on May 29, 2024, and the total return since then is +685.10%. Beta against the wider market is reported at 3.82. Daily returns over the trailing 2 years annualize to a volatility of 100.53%.

Growth & Income

The record shows no dividend for INBX.

So far in 2026 the total return is +24.29%. The record holds one complete calendar year, 2025, which returned +412.99%.

Peer Comparison

Inhibrx Biosciences, Inc. (INBX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Inhibrx Biosciences, Inc. INBX $1.45B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Inhibrx Biosciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.

Visit website →